Sep 21, 2021 9:00 am EDT Skye Bioscience Announces THCVHS Late-Breaking Preclinical Abstracts Selected by American Association of Pharmaceutical Scientists Meeting PharmSci 360
Sep 7, 2021 8:30 am EDT Skye Bioscience to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Jul 26, 2021 8:30 am EDT Skye Bioscience Appoints Biotech Executive Praveen Tyle, Ph.D. to Board of Directors
Jun 10, 2021 8:30 am EDT Skye Bioscience Expands Clinical Advisory Board with the Appointment of Ophthalmology Expert Dr. Miguel González-Andrades
May 17, 2021 8:42 am EDT Skye Bioscience’s THCVHS Demonstrates Superior Therapeutic Benefit Compared to Glaucoma Standard of Care, both as Combination and Single Agent, in Preclinical Study